RxDoctor Payments Data

Stephanie McCardle, MD

Family Medicine · Brownsburg, INNPI 1053342543

Payments from drug & device makers

$648in general payments, 2019–2025

Across 39 payments — averaging $16.60 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$142
  • Novo Nordisk$136
  • Johnson & Johnson$121
  • Pfizer$88
  • Eisai Inc.$23
  • Astellas Pharma US Inc$20
  • plus $117 from 8 others

What the payments were for

  • Food & beverage$648100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$648 in reported general payments places this provider in the 50th percentile of 2,709 family medicine providers in Indiana.

See all family medicine providers in Indiana

Medicare billing

Part B allowed, 2024
$18,744
Medicare patients
104
Services billed
265

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide88$96,991
JardianceEmpagliflozin86$80,025
Trelegy ElliptaFluticasone/Umeclidin/Vilanter57$64,396
EliquisApixaban83$57,274
MounjaroTirzepatide31$50,088
MyrbetriqMirabegron68$37,435
TrulicityDulaglutide20$32,033
XareltoRivaroxaban21$22,755
EntrestoSacubitril/Valsartan37$17,535
JanuviaSitagliptin Phosphate20$11,422
Breo ElliptaFluticasone/Vilanterol15$11,362
FarxigaDapagliflozin Propanediol13$10,959
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr15$8,012
GemtesaVibegron13$7,892
Lantus SolostarInsulin Glargine,hum.Rec.Anlog64$6,021

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$136$96,99188 claims
GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta$14$83,77087 claims
Lilly USA, LLCMounjaro, Trulicity$11$82,12151 claims
Boehringer IngelheimJardiance$16$80,02586 claims
PfizerEliquis$88$57,27483 claims
Astellas Pharma US IncMyrbetriq$20$37,43568 claims
Johnson & JohnsonXarelto$121$22,75521 claims
AstraZenecaFarxiga, Symbicort$19$16,74237 claims
AbbVieCreon$142$3,49711 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 2,709 family medicine providers in Indiana.

Other family medicine in Brownsburg

See the full list for Indiana

Where these figures come from

Is this you, or does something look wrong? →